SHIB at $0.00000561 targets $0.000015 by year-end 2026 — but only if Shibarium TVL ($1.44M) and daily transactions grow by ...
This report is an independent strategic market study that provides a structured, commercially grounded analysis of the market for Barium CT Contrast Agents in Japan. It is designed for manufacturers, ...
An update from Voyageur Pharmaceuticals ( (TSE:VM)) is now available. Voyageur Pharmaceuticals has outlined a strategic roadmap to build a vertically integrated supply chain for barium and iodine ...
Voyageur Pharmaceuticals Advances Vertical Integration Strategy for Barium and Iodine Contrast Media
Voyageur Pharmaceuticals is progressing toward establishing North America's first vertically integrated supply chain for barium and iodine contrast media drugs, addressing critical vulnerabilities in ...
CALGARY, AB - March 16, 2026 (NEWMEDIAWIRE) - Voyageur Pharmaceuticals Ltd. (TSX-V: VM) (OTC Pink: VYYRF) (the "Company" or "Voyageur"), a pharmaceutical company focused on developing barium and ...
Calgary, Alberta, Canada – TheNewswire – March 16, 2026 - Voyageur Pharmaceuticals Ltd. (TSX-V: VM) (OTC Pink: VYYRF) (the "Company" or "Voyageur"), a pharmaceutical company focused on developing ...
Voyageur Completes Human Testing of Barium Contrast Products and Prepares for Canadian Market Launch
Calgary, Alberta, Canada – April 1, 2025 –TheNewswire -Voyageur Pharmaceuticals Ltd. (VM:CA) (OTC Pink:VYYRF) ("Voyageur" or the "Company") is pleased to announce the successful completion of a key ...
Calgary, Alberta, Canada – April 23, 2025 – TheNewswire - Voyageur Pharmaceuticals Ltd. (TSX.V:VM) (OTC Pink:VYYRF) ("Voyageur" or the "Company") a radiology contrast media company focused on vertical ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results